Characteristics of individual studies at the time of randomisation
| Study | No of patients | Age(years) | Women(%) | Current smoker (%) | FEV1 (l)* | FEV1 (% of predicted)*† | Mortality(%) | Follow up(months) | Drug/dose |
|---|---|---|---|---|---|---|---|---|---|
| LHS-2, Lung Health Study 2; CCLS, Copenhagen City Lung Study; ISOLDE, Inhaled Steroids in Obstructive Disease in Europe; EUROSCOP, European Respiratory Society Study on Chronic Obstructive Pulmonary Disease; TRISTAN, TRial of Inhaled STeroids ANd long acting β2 agonists; FEV1, forced expiratory volume in 1 second. | |||||||||
| *Post-bronchodilator values. | |||||||||
| †Values may differ slightly from the original publications because we applied Hankinson’s prediction equation to all of the “raw” FEV1 values. | |||||||||
| Continuous variables are presented as mean (SD) and dichotomous variables as percentage of participants in each individual trial. | |||||||||
| LHS-2 | 1116 | 56 (7) | 37 | 90 | 2.3 (0.6) | 67 (13) | 2.8 | 42 (5) | Triamcinolone (1200 μg/day) |
| CCLS | 290 | 59 (9) | 40 | 76 | 2.4 (0.8) | 76 (18) | 2.8 | 30 (12) | Budesonide (867 μg/day) |
| ISOLDE | 751 | 64 (7) | 25 | 48 | 1.4 (0.5) | 49 (14) | 13.7 | 34 (7) | Fluticasone (1000 μg/day) |
| EUROSCOP | 1277 | 52 (8) | 27 | 100 | 2.6 (0.7) | 73 (13) | 1.5 | 28 (13) | Budesonide (800 μg/day) |
| TRISTAN | 735 | 63 (9) | 28 | 50 | 1.4 (0.5) | 46 (13) | 2.0 | 10 (4) | Fluticasone (1000 μg/day) |
| Szafranski | 403 | 64 (9) | 18 | 30 | 1.0 (0.4) | 36 (12) | 3.5 | 9 (4) | Budesonide (800 μg/day) |
| Calverley | 513 | 64 (9) | 26 | 31 | 1.2 (0.5) | 42 (15) | 2.1 | 9 (5) | Budesonide (800 μg/day) |
| Total | 5085 | 59 (9) | 29 | 69 | 1.9 (0.8) | 58 (19) | 4.0 | 26 (15) | |